Onesource Specialty Pharma Ltd.
NSE: ONESOURCE
Prev Close
1514.9
Open Price
1498
Volume
277,137
Today Low / High
1445.8 / 1536.6
52 WK Low / High
1057 / 2248
Range
1,400 - 1,548
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 1473.9, with a change of -41 (-2.70645%). The expected target range on the NSE is between 1,400 - 1,548. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
Onesource Specialty Pharma Ltd. Graph
Onesource Specialty Pharma Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Onesource Specialty Pharma Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,473.90, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,473.90 | 1,488.64 | 1,339.78 - 1,637.50 |
| 1,503.38 | 1,202.70 - 1,804.05 | ||
| 1,518.12 | 1,062.68 - 1,973.55 | ||
| Bearish Scenario | 1,473.90 | 1,459.16 | 1,313.24 - 1,605.08 |
| 1,444.42 | 1,155.54 - 1,733.31 | ||
| 1,429.68 | 1,000.78 - 1,858.59 |
Overview of Onesource Specialty Pharma Ltd.
ISIN
INE013P01021
Industry
Biotechnology
Vol.Avg
315,472
Market Cap
150,096,461,400
Last Dividend
0
Official Website
IPO Date
2025-01-24
DCF Diff
1,444.22
DCF
-135
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,444.85 Cr | 435.03 Cr | 1,009.82 Cr | 0.6989 | 2.05 Cr | 98.56 Cr | 190.44 Cr | -0.21 Cr | -0.02 | 360.96 Cr | -0.0001 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 156.48 Cr | 7,550.24 Cr | 20.97 Cr | 5,880.5790 Cr | 942.44 Cr | 785.96 Cr | 158.06 Cr | 1,004.40 Cr | 0.00 Cr | 2.56 Cr | 0.74 Cr | 13.0182 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -2.4687 Cr | -2.5054 Cr | 6.6467 Cr | -196.0020 Cr | 143.0950 Cr | 165.3590 Cr | -128.1480 Cr | -67.7560 Cr | -285.9850 Cr | 0.0000 Cr | 43.9930 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 290.34 Cr | 228.20 Cr | 62.15 Cr | 0.2140 | -52.32 Cr | -88.70 Cr | -7.74 | 17.32 Cr | -0.3055 |
| 2025-09-30 | 375.76 Cr | 113.49 Cr | 262.27 Cr | 0.6980 | 36.67 Cr | 10.49 Cr | 0.92 | 109.53 Cr | 0.0279 |
| 2025-06-30 | 327.27 Cr | 92.92 Cr | 234.35 Cr | 0.7161 | 20.68 Cr | -0.19 Cr | -0.02 | 90.88 Cr | -0.0006 |
| 2025-03-31 | 425.95 Cr | 230.46 Cr | 195.50 Cr | 0.4590 | 114.02 Cr | 98.50 Cr | 8.61 | 182.52 Cr | 0.2313 |
| 2024-09-30 | 334.05 Cr | 123.90 Cr | 210.15 Cr | 0.6291 | 9.54 Cr | -42.08 Cr | -3.68 | 75.88 Cr | -0.1260 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 103.55 Cr | 76.06 Cr | 179.60 Cr | 664.33 Cr | 325.33 Cr | 1,354.66 Cr | 1,093.95 Cr | 8,013.30 Cr | 2,108.83 Cr |
| 2025-03-31 | 156.48 Cr | 8.88 Cr | 309.78 Cr | 447.81 Cr | 158.06 Cr | 1,086.18 Cr | 1,004.40 Cr | 7,550.24 Cr | 1,669.66 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹395.80 | ₹502,336,973,043.00 | ₹3,554,697.00 |
| Anthem Biosciences Ltd. | ANTHEM | ₹670.15 | ₹376,432,537,248.00 | ₹141,357.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹155.37 | ₹205,611,590,763.00 | ₹1,450,331.00 |
| Onesource Specialty Pharma Ltd. | ONESOURCE | ₹1,473.90 | ₹168,940,186,680.00 | ₹277,137.00 |
| Syngene International Limited | SYNGENE | ₹409.30 | ₹164,437,005,191.00 | ₹675,182.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,197.20 | ₹125,246,519,429.00 | ₹100,555.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹570.75 | ₹90,184,712,614.00 | ₹363,355.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹376.10 | ₹65,240,346,343.00 | ₹357,325.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹604.80 | ₹48,675,997,440.00 | ₹105,837.00 |
| Zota Health Care Limited | ZOTA | ₹1,176.70 | ₹35,692,435,139.00 | ₹47,409.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹164.51 | ₹25,792,386,958.00 | ₹431,232.00 |
Key Executives
Gender: Not Specified
Year Born:
Gender: male
Year Born: 1972
Gender: male
Year Born: 1961
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1972
Gender: male
Year Born:
Gender: female
Year Born:
FAQs about Onesource Specialty Pharma Ltd.
The CEO is Neeraj Sharma.
The current price is ₹1,309.50.
The range is ₹1057-2248.
The market capitalization is ₹15,009.65 crores.
The P/E ratio is 746.41.
The company operates in the Healthcare sector.
Overview of Onesource Specialty Pharma Ltd. (ISIN: INE013P01021) is a leading Biotechnology in India. With a market capitalization of ₹15,009.65 crores and an average daily volume of 315,472 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.